Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.

A surge in clinical trials investigating potential idiopathic pulmonary fibrosis therapies offers patients new hope, according to a recently published review.

Rein Therapeutics has initiated the randomised RENEW Phase II trial of its Caveolin-1-related peptide, LTI-03, targeting ...

Chugai files regulatory application with Japanese MHLW for additional indication of Tecentriq to treat thymic carcinoma: Tokyo Tuesday, May 20, 2025, 15:00 Hrs [IST] Chugai Pharma ...

The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed ...

RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) initiated with topline interim data expected ...

Rein Therapeutics initiates RENEW phase 2 trial of LTI-03 in patients with idiopathic pulmonary fibrosis: Austin, Texas Tuesday, May 13, 2025, 18:00 Hrs [IST] Rein Therapeutics (R ...